文献速递消化系统肿瘤骨软组织肉瘤与黑色素瘤

Neopepsee:整合序列与氨基酸免疫原性信息的基因组级新抗原精准预测

Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.
PubMed 文献 · Ann Oncol · 2018-01-01

研究开发了基于机器学习的Neopepsee新抗原预测程序,利用RNA-seq数据与体细胞突变列表提取突变肽序列及表达水平,构建免疫原性分类器并与基于IC50的传统方法比较。结果显示其敏感性提升、特异性提高两至三倍,并在黑色素瘤与慢性淋巴细胞白血病验证数据中证实性能,应用于224例胃腺癌预测每例约7个新抗原且负荷与预后相关。

要点

  • Neopepsee较基于IC50的传统方法敏感性提升,特异性提高两至三倍。
  • 在黑色素瘤和慢性淋巴细胞白血病验证数据中证实预测性能改善。
  • 224例胃腺癌中每例约预测7个新抗原,负荷与患者预后相关。

核心结论

  • Neopepsee可检出假阳性更少的新抗原候选,并可用于判断患者预后。

研究设计与样本

  • 基于机器学习的新抗原预测程序,利用RNA-seq原始数据与体细胞突变列表自动提取突变肽序列和基因表达水平。
  • 测试14个免疫原性特征构建机器学习分类器,并与基于IC50的传统方法比较敏感性和特异性。
  • 在黑色素瘤、白血病和胃癌的独立数据集上测试Neopepsee。

主要发现

  • 14个免疫原性特征中9个信息量大且相互独立,用于构建机器学习分类器。
  • Neopepsee提供候选肽的丰富注释,含87项免疫原性相关数值,包括IC50、新肽与免疫调控基因(如PD1、PD-L1)表达水平、匹配表位序列及高/中/低三级新抗原概率判定。
  • 与常规方法相比性能提升,敏感性提高,特异性尤其提高两至三倍。
  • 在黑色素瘤与慢性淋巴细胞白血病的验证数据集和独立证实的新抗原中确认性能改善。
  • 发现蛋白序列与已知病原表位的相似性可作为分类的新特征。

关键数值与推荐

  • 14个免疫原性特征中9个用于构建机器学习分类器。
  • Neopepsee输出87项免疫原性相关数值注释及三级新抗原概率判定。
  • 特异性较传统方法提高两至三倍。
  • 224例胃腺癌中每例约预测7个新抗原。

临床怎么用

  • 可用于从测序数据中检出假阳性更少的新抗原候选,辅助预测患者预后。
  • 有望推动下一代癌症免疫治疗、预测性生物标志物及个体化癌症疫苗研究。

局限性

  • 摘要未报告分类器具体算法、训练集规模及敏感性提升的具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor-specific mutations form novel immunogenic peptides called neoantigens. Neoantigens can be used as a biomarker predicting patient response to cancer immunotherapy. Although a predicted binding affinity (IC50) between peptide and major histocompatibility complex class I is currently used for neoantigen prediction, large number of false-positives exist. MATERIALS AND METHODS: We developed Neopepsee, a machine-learning-based neoantigen prediction program for next-generation sequencing data. With raw RNA-seq data and a list of somatic mutations, Neopepsee automatically extracts mutated peptide sequences and gene expression levels. We tested 14 immunogenicity features to construct a machine-learning classifier and compared with the conventional methods based on IC50 regarding sensitivity and specificity. We tested Neopepsee on independent datasets from melanoma, leukemia, and stomach cancer. RESULTS: Nine of the 14 immunogenicity features that are informative and inter-independent were used to construct the machine-learning classifiers. Neopepsee provides a rich annotation of candidate peptides with 87 immunogenicity-related values, including IC50, expression levels of neopeptides and immune regulatory genes (e.g. PD1, PD-L1), matched epitope sequences, and a three-level (high, medium, and low) call for neoantigen probability. Compared with the conventional methods, the performance was improved in sensitivity and especially two- to threefold in the specificity. Tests with validated datasets and independently proven neoantigens confirmed the improved performance in melanoma and chronic lymphocytic leukemia. Additionally, we found sequence similarity in proteins to known pathogenic epitopes to be a novel feature in classification. Application of Neopepsee to 224 public stomach adenocarcinoma datasets predicted ∼7 neoantigens per patient, the burden of which was correlated with patient prognosis. CONCLUSIONS: Neopepsee can detect neoantigen candidates with less false positives and be used to determine the prognosis of the patient. We expect that retrieval of neoantigen sequences with Neopepsee will help advance research on next-generation cancer immunotherapies, predictive biomarkers, and personalized cancer vaccines.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Kim S, Kim HS, Kim E, et al. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information. Ann Oncol. 2018. PMID: 29360924. doi:10.1093/annonc/mdy022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。